Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We work at the interface of biotechnology and biomedicine. Our major focus is on RNA biology and RNA therapeutics as applied primarily to rare neuromuscular diseases.


We are interested in the development of RNA therapeutic technologies and in particular technologies for targeted intracellular delivery of RNA therapies (antisense oligonucleotides, gene silencing RNAi therapies and gene editing therapies) to cells and tissues of the neuromuscular system (muscle, heart and brain). These intracellular delivery technologies include development of novel cell-targeting peptides, antibody conjugates and the engineering of extracellular vesicles (EVs) for drug delivery and targeted cellular uptake. Much of our recent work has focussed on Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA) and myotonic dystrophy type 1 (DM1) in addition to which we have emerging areas of interest in Huntington’s disease and motor neuron disease (ALS).




AKTA Start© AKTA StartAKTA Start